Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    9272483 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
Condition: Parkinson's Disease
Interventions: Drug: carbidopa/l-dopa;   Drug: carbidopa/l-dopa/entacapone;   Drug: Stalevo;   Procedure: [123I]-IBZM imaging

Indicates status has not been verified in more than two years